Radiopharmaceutical therapy is rapidly advancing oncology drug development by enabling highly targeted radiation delivery to tumors while sparing healthy tissue through a theranostic, precision medicine approach.

Recent clinical successes and FDA approvals have accelerated momentum, expanding use into earlier lines of treatment and increasing interest across a broader range of tumor targets. At the same time, updated FDA guidance is reshaping development expectations, with greater emphasis on early dose optimization, quantitative dosimetry, extended safety follow‑up, and proactive regulatory engagement. Alongside these scientific and regulatory advances, sponsors must address unique operational challenges including radioactive material handling, just‑in‑time manufacturing and distribution, site readiness, and coordination of imaging and dosimetry, making integrated strategy and execution essential to bringing these therapies successfully to patients.

Read this white paper in full, to learn more.